Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk (Q24245375)

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Involved-field radiotherapy for advanced Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Current clinical trials for the treatment of adult advanced-stage Hodgkin's disease: GELA experiences. Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Second lethal events associated with treatment for Hodgkin's disease: a review of 2980 patients treated in a single Mexican institute

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Combination chemotherapy and radiotherapy for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Treatment of stages I and II Hodgkin's disease with three different therapeutic modalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

MOPP/ABVD chemotherapy for advanced Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

The intergroup Hodgkin's disease in children. A study of stages I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Combined modality treatment of Hodgkin's disease confined to lymph nodes. Results eight years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

The treatment of stage IIIA Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Breast cancer and other second neoplasms after childhood Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Gastrointestinal cancer after treatment of Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Carcinogenesis--a synopsis of human experience with external exposure in medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Solid cancer risk after treatment of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Incidence of second cancers in patients treated for Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Breast cancer after treatment of Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

How relevant is secondary leukaemia for initial treatment selection in Hodgkin's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Leukemia following Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Lung cancer following Hodgkin's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Current therapies in Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

A meta-analysis of stages I and II Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

A cure model with time-changing risk factor: an application to the analysis of secondary leukaemia. A report from the International Database on Hodgkin's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Second cancer risk following Hodgkin's disease: a 20-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Second Malignant Neoplasms Among Long-Term Survivors of Hodgkin’s Disease: A Population-Based Evaluation Over 25 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease

21 January 2018

1 reference

12 December 2020

Malignancy: Adjuvant Radiotherapy to Initial Bulky Disease in Patients with Advanced Stage Hodgkin's Disease

1 reference

12 December 2020

Hodgkin's lymphoma: evolving concepts with implications for practice.

1 reference

12 December 2020

A randomised study of adjuvant MVPP chemotherapy after mantle radiotherapy in pathologically staged IA-IIB Hodgkin's disease: 10-year follow-up

1 reference

12 December 2020

Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study

1 reference

12 December 2020

The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease

1 reference

12 December 2020

International Symposium on Hodgkin's Disease. Session 5. Treatment. Current status of clinical trials: Stanford experience, 1962-72

1 reference

12 December 2020

Radiotherapy of stage I and II Hodgkin's disease. A collaborative study

1 reference

12 December 2020

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy

1 reference

12 December 2020

The management of stage IIIA Hodgkin's disease

1 reference

12 December 2020

Management of early stage Hodgkin's disease: the role of radiation therapy and/or chemotherapy

1 reference

12 December 2020

Combined radio- and chemotherapy of patients with stage I-II lymphogranulomatosis

1 reference

12 December 2020

The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a cas

1 reference

12 December 2020

Combination chemotherapy-radiotherapy for stage 3 Hodgkin's disease. An acute leukemia group B study

1 reference

12 December 2020

Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study

1 reference

12 December 2020

Multiple chemotherapy (MOPP) followed by either focal or selective radiotherapy in clinical stages IA and II2A of Hodgkin's disease: results after four years of the use of prospective schedule (H 7701) in 79 patients (author's transl)

1 reference

12 December 2020

Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: eight-year update of an Italian prospective randomized study

1 reference

12 December 2020

Initial treatment of stage IIIA Hodgkin's disease. Comparison of radiotherapy with combined chemotherapy. British National Lymphoma Investigation

1 reference

12 December 2020

Acute leukemia after the treatment of Hodgkin's disease.

1 reference

12 December 2020

Stage I and II Hodgkin's disease: involved-field radiotherapy versus extended-field radiotherapy versus involved-field radiotherapy followed by six cycles of MOPP

1 reference

12 December 2020

Conclusions from clinical trials of the Southwest Oncology Group

1 reference

12 December 2020

Treatment of Hodgkin's disease. Experience of the Hôpital Saint-Louis

1 reference

12 December 2020

Radiotherapy versus radiotherapy plus chemotherapy in stages I and II Hodgkin's disease. A prospective, randomized study by the Danish National Hodgkin Study Group, LYGRA.

1 reference

12 December 2020

The risk of non-Hodgkin's lymphoma after Hodgkin's disease, with special reference to splenic treatment

1 reference

12 December 2020

Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'études des lymphomes de l'Adulte H89 trial

1 reference

12 December 2020

Pathologic stages IA and IIA Hodgkin's disease: results of treatment with radiotherapy alone (1968-1980)

1 reference

12 December 2020

A combined modality approach to the treatment of Hodgkin's disease.Preliminary results of a prospectively randomized clinical trial

1 reference

12 December 2020

The Pediatric Oncology Group. Studies in Hodgkin's disease.

1 reference

12 December 2020

Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease

1 reference

12 December 2020

Long-term cause-specific mortality of patients treated for Hodgkin's disease

1 reference

12 December 2020

Hodgkin's disease clinical trial

1 reference

12 December 2020

Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG)

1 reference

12 December 2020

Collaborative clinical trial for stage I and II Hodgkin's disease: significance of mediastinal and nonmediastinal disease in laparotomy- and non-laparotomy-staged patients

1 reference

12 December 2020

A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease

1 reference

12 December 2020

Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?

1 reference

12 December 2020

Sequential radiotherapy and chemotherapy in the treatment of Hodgkin's disease. A progress report

1 reference

12 December 2020

Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies

1 reference

12 December 2020

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

1 reference

12 December 2020

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie

1 reference

12 December 2020

Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution

1 reference

12 December 2020

Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease

1 reference

12 December 2020

Hodgkin's lymphoma: basing the treatment on the evidence

1 reference

12 December 2020

Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence

1 reference

12 December 2020

Intergroup Hodgkin's disease in children study of stages I and II: a preliminary report

1 reference

12 December 2020

The management of stages I, II, and III Hodgkin's disease with combined radiotherapy and chemotherapy

1 reference

12 December 2020

Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Comparison of total nodal irradiation versus combined sequence of mantle irradiation with mechlorethamine, vincristine, procarbazine, and prednisone in clinical stages I and II Hodgkin's disease: experience of the European Organization for Research

1 reference

12 December 2020

The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group

1 reference

12 December 2020

Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study

1 reference

12 December 2020

Prognostic classification of Hodgkin disease in pathologic stage III, based on anatomic considerations

1 reference

12 December 2020

Combined modality (ABVD plus radiotherapy) versus radiotherapy in the management of early stage (IIA) Hodgkin's disease with mediastinal involvement

1 reference

12 December 2020

[Late results of drug and combined (chemo- and radio-) therapy of stages IIIB-IV of lymphogranulomatosis]

1 reference

12 December 2020

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

1 reference

12 December 2020

Progress report. Hodgkin's clinical trial, 1972

1 reference

12 December 2020

Radiotherapy in 50 cases of Hodgkin's disease in stages I and II. Report from the Lymphogranulomatosis Committee (LYGRA)

1 reference

12 December 2020

[Treatment of patients with lymphogranulomatosis, stages I and II (preliminary results of a randomized study--radiation and complex therapy)]

1 reference

12 December 2020

Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease

1 reference

12 December 2020

Radiotherapy or chemotherapy as the initial treatment for stage IIIA Hodgkin's disease (Report no 13)

1 reference

12 December 2020

Evaluation of therapeutic modalities in the control of Hodgkin's disease

1 reference

12 December 2020

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymph

1 reference

12 December 2020

Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age

1 reference

12 December 2020

Late complications after Hodgkin's disease.

1 reference

12 December 2020

Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.

1 reference

12 December 2020

Risk of second cancers after treatment for Hodgkin's disease

1 reference

12 December 2020

Occurrence of acute nonlymphocy tic leukemia in a prospective randomized study of treatment for Hodgkinʼs disease

1 reference

12 December 2020

The Stanford Hodgkin's disease (HD) studies--an update

1 reference

12 December 2020

A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease

1 reference

12 December 2020

Large mediastinal mass in Hodgkin's disease. Results of two treatment modalities

1 reference

12 December 2020

Hodgkin's disease in Denmark. A national clinical study by the Danish Hodgkin Study Group, LYGRA

1 reference

12 December 2020

Treatment of stage I and II mediastinal Hodgkin disease. A comparison of involved fields, extended fields, and involved fields followed by MOPP in patients staged by laparotomy

1 reference

12 December 2020

Hodgkin's disease in childhood and adolescence: results of chemotherapy-radiotherapy in clinical stages IA-IIB

1 reference

12 December 2020

Hodgkin's disease: study of treatment intensities and incidences of second malignancies

1 reference

12 December 2020

Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival--results of a Cancer and Leukemia Group B study

1 reference

12 December 2020

The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience

1 reference

12 December 2020

Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials

1 reference

12 December 2020

Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors

1 reference

12 December 2020

EORTC Lymphoma Cooperative Group studies in clinical stage I-II Hodgkin's disease 1963-1987.

1 reference

12 December 2020

The efficiency of different combined treatment programs (combination chemotherapy-radiotherapy) used for stage I-II Hodgkin's disease

1 reference

12 December 2020

The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.

1 reference

12 December 2020

Current Stanford clinical trials for Hodgkin's disease.

1 reference

12 December 2020

Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group

1 reference

12 December 2020

High risk of breast carcinoma after irradiation of young women with Hodgkin's disease

1 reference

12 December 2020

Late complications of therapy of Hodgkin's disease: prevention and management

1 reference

12 December 2020

Solid second cancers following Hodgkin's disease

1 reference

12 December 2020

Results of involved field and extended field radiotherapy in patients with pathologic state I and II Hodgkin's disease

1 reference

12 December 2020

MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial

1 reference

12 December 2020

Adjuvant Radiotherapy to Initial Bulky Disease in Patients with Advanced Stage Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

7 January 2021

inferred from DOI database lookup

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003187.PUB2

7 January 2021